Literature DB >> 16870507

Staphylococcal vaccines and immunotherapy: to dream the impossible dream?

Steven J Projan1, Mirjana Nesin, Paul M Dunman.   

Abstract

Staphylococcal infections not only remain an important cause of morbidity and mortality in both the community and the clinic, but the emergence of a global pandemic of community-associated methicillin-resistant Staphylococcus aureus, involving what purports to be a more virulent strain of this organism, has also led several in the infectious disease community to call for improved disease prevention strategies (in addition to novel therapeutics) in what could be thought of as the microbiological version of pre-emption. In this case, Staphylococcus aureus possesses "weapons of mass destruction" and appears to be using them effectively as part of anti-immunization insurgency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16870507     DOI: 10.1016/j.coph.2006.04.005

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  34 in total

Review 1.  Exploring Staphylococcus aureus pathways to disease for vaccine development.

Authors:  Andrea DeDent; Hwan Keun Kim; Dominique Missiakas; Olaf Schneewind
Journal:  Semin Immunopathol       Date:  2011-12-01       Impact factor: 9.623

2.  Determinants of murein hydrolase targeting to cross-wall of Staphylococcus aureus peptidoglycan.

Authors:  Matthew B Frankel; Olaf Schneewind
Journal:  J Biol Chem       Date:  2012-02-02       Impact factor: 5.157

3.  Identifying protective antigens of Staphylococcus aureus, a pathogen that suppresses host immune responses.

Authors:  Hwan Keun Kim; Hye-Young Kim; Olaf Schneewind; Dominique Missiakas
Journal:  FASEB J       Date:  2011-07-13       Impact factor: 5.191

4.  The potential economic value of a Staphylococcus aureus vaccine for neonates.

Authors:  Bruce Y Lee; Paul J Ufberg; Rachel R Bailey; Ann E Wiringa; Kenneth J Smith; Andrew J Nowalk; Conor Higgins; Angela R Wateska; Robert R Muder
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

5.  Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice.

Authors:  Lorena P N Tuchscherr; Fernanda R Buzzola; Lucía P Alvarez; Jean C Lee; Daniel O Sordelli
Journal:  Infect Immun       Date:  2008-09-22       Impact factor: 3.441

6.  Targeting pili in enterococcal pathogenesis.

Authors:  Kenneth L Pinkston; Kavindra V Singh; Peng Gao; Nathaniel Wilganowski; Holly Robinson; Sukhen Ghosh; Ali Azhdarinia; Eva M Sevick-Muraca; Barbara E Murray; Barrett R Harvey
Journal:  Infect Immun       Date:  2014-01-22       Impact factor: 3.441

7.  A MRSA-terious enemy among us: boosting MRSA vaccines.

Authors:  Scott D Kobayashi; Frank R DeLeo
Journal:  Nat Med       Date:  2011-02       Impact factor: 53.440

8.  Deriving a dose and regimen for anti-glucosaminidase antibody passive-immunisation for patients with Staphylococcus aureus osteomyelitis.

Authors:  C C Lee; R D Southgate; C Jiao; E Gersz; J R Owen; S L Kates; C A Beck; C Xie; J L Daiss; V Post; T F Moriarty; S Zeiter; E M Schwarz; G Muthukrishnan
Journal:  Eur Cell Mater       Date:  2020-01-31       Impact factor: 3.942

9.  Protein A-neutralizing monoclonal antibody protects neonatal mice against Staphylococcus aureus.

Authors:  Vilasack Thammavongsa; Sabine Rauch; Hwan Keun Kim; Dominique M Missiakas; Olaf Schneewind
Journal:  Vaccine       Date:  2014-12-06       Impact factor: 3.641

Review 10.  Models matter: the search for an effective Staphylococcus aureus vaccine.

Authors:  Wilmara Salgado-Pabón; Patrick M Schlievert
Journal:  Nat Rev Microbiol       Date:  2014-07-07       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.